# Japan frequency-healing hospital claim: source-review notes

Reviewed October 16, 2026 for Managing Expectations Health. Public-interest reporting; not medical advice. No manufacturer, pharmaceutical company or regulator was contacted. No product endorsement or treatment recommendation is made.

## Original source and capture

https://www.instagram.com/reel/DejtBXliaT2/

Account identified by public metadata as Jason Shurka / therealjasonshurka. Metadata dates the post October 16, 2026. The complete downloadable media was captured with yt-dlp: ffprobe reported 69.1 seconds, 720x1280 video and AAC audio. Machine-assisted English transcription covered the clip through approximately 69 seconds; representative frames were inspected. Public caption and visual overlays were recorded separately. Raw video, metadata, transcript and frames are retained locally, not republished as medical evidence. Unrelated comments, personal account details and signed CDN URLs are excluded from this public note.

The Reel claims nationwide Japanese hospital adoption, an alleged Pfizer protest, a quotation attributed to JPMA, and broad regeneration/DNA/immune benefits. It ends by directing viewers to a commercial wellness-device website. Its claims are described as claims, not established findings.

## Japan claim verification

Primary records examined:
- MHLW July announcements: https://www.mhlw.go.jp/stf/houdou/houdou_list_202607.html
- MHLW September announcements: https://www.mhlw.go.jp/stf/houdou/houdou_list_202609.html
- PMDA regulatory pathway: https://www.pmda.go.jp/english/review-services/reviews/0004.html
- PMDA FY2026 new-device page: https://www.pmda.go.jp/review-services/drug-reviews/review-information/devices/0061.html
- PMDA FY2026 improved-device page: https://www.pmda.go.jp/review-services/drug-reviews/review-information/devices/0062.html
- Pfizer Japan public releases: https://www.pfizer.co.jp/pfizer/company/press
- JPMA public releases: https://www.jpma.or.jp/news_room/release/2026/index.html

No corresponding nationwide authorization, implementation document, protest or attributed quotation was located in the reviewed material and targeted English/Japanese searches. This is lack of corroboration, not proof that a private communication or every possible document does not exist. Retrieved PMDA FY2026 tables covered April–June and cannot exclude a July approval. English translated-review lists are selected, not comprehensive. Press archives are not exhaustive internal records.

A July 19 third-party post https://roserambles.org/2026/07/19/japan-just-became-the-first-country-to-officially-approve-medbed-technology-for-public-hospitals-july-19-2026/ carries the related MHLW-2026-7714/July 17/September 1/340-hospital narrative. It was read only as evidence of circulation, not as proof of authorization. The Reel does not itself give those dates, number or directive identifier. No claim is made that this particular page is the Reel's direct source.

## Real clinical and research context

- NCI, November 4, 2020: https://ccr.cancer.gov/news/article/japan-approves-photoimmunotherapy-for-head-and-neck-cancer — the institutional report identifies Akalux plus BioBlade and a defined head-and-neck-cancer indication. Text recovered through web extraction; a separate direct HTTP request returned 403. Historical approval account, not an exhaustive current label/availability review. Not established as the origin of the viral story.
- FDA NeuroStar de novo document: https://www.accessdata.fda.gov/cdrh_docs/pdf6/k061053.pdf — historical prescription TMS authorization for defined depression patients. Not a comprehensive account of current labels.
- Stupp et al. 2017: https://pubmed.ncbi.nlm.nih.gov/29260225/ — 695 randomized glioblastoma patients; TTFields added to maintenance temozolomide after radiochemotherapy. Median overall survival from randomization 20.9 vs 16.0 months. Open-label, manufacturer-involved study; not a universal cure. Parent verification also recovered the indexed abstract via Europe PMC's API.
- NCCIH: https://www.nccih.nih.gov/health/magnets-for-pain-what-you-need-to-know — specific PEMF uses, heterogeneous evidence and pacemaker/insulin-pump interference cautions. Direct page retrieved.
- Son et al. 2025: https://doi.org/10.1186/s13643-025-02902-3 and https://europepmc.org/articles/PMC12326686 — 15 meta-analyses, 204 RCTs, over 9,000 participants. Searches through December 8, 2023. Evidence from very low to moderate; none high-certainty. Safety could not be adequately assessed from included meta-analyses. PubMed direct access was challenged/rate-limited; full article XML and abstract were recovered from Europe PMC. These are photobiomodulation findings, not validation of TLS.

## Commercial source assessment

https://www.thelightsystems.com/
https://www.thelightsystems.com/biological-efficacy-of-the-light-system
https://www.thelightsystems.com/research
https://www.thelightsystems.com/disclaimer

Pages directly retrieved. The Chair page describes a subject, cheek-cell sampling, EIS readings, repeated measurements and exposure conditions. This is not evidence of repaired DNA mutations or clinical immune restoration. Reported conductivity findings are attributed to the seller; they were not independently replicated in this review. The homepage says the technology is not intended to diagnose, treat, cure or prevent disease, and the separate disclaimer states no medical claims are made. No intent-to-deceive allegation is asserted.

## Publication controls

Original editorial SVG, not a depiction of an actual medical device or clinical result. Article and source note separate evidence classes and identify access limitations. Raw third-party pages and social comments are not in the public package. Existing related frequency-detox article is linked rather than replaced. Only the article, image, source note and scoped discovery files are updated; remote backups and live content checks are required.